Short Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Increases By 36.1%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 4,150,000 shares, an increase of 36.1% from the January 31st total of 3,050,000 shares. Based on an average trading volume of 723,400 shares, the short-interest ratio is presently 5.7 days. Currently, 5.2% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of research analyst reports. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $25.83.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the transaction, the chief executive officer now owns 331,017 shares of the company’s stock, valued at approximately $5,273,100.81. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Karen M. Anderson sold 5,876 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $17.01, for a total transaction of $99,950.76. Following the completion of the sale, the insider now directly owns 71,525 shares of the company’s stock, valued at $1,216,640.25. The trade was a 7.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 446,682 shares of company stock worth $7,632,282 over the last 90 days. Insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $20,994,000. Franklin Resources Inc. boosted its stake in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after acquiring an additional 924,027 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Up 2.8 %

NASDAQ CNTA traded up $0.47 during trading on Wednesday, hitting $16.80. The stock had a trading volume of 682,076 shares, compared to its average volume of 816,547. Centessa Pharmaceuticals has a 12 month low of $7.75 and a 12 month high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company’s 50-day moving average price is $16.50 and its two-hundred day moving average price is $16.09. The company has a market capitalization of $2.21 billion, a PE ratio of -10.98 and a beta of 1.53.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.